To treat heart failure (HF) effectively, symptoms must first be recognized and followed with an appropriate, timely diagnosis. As well, guideline-directed management must be implemented. The implementation of these recommendations is crucial for maximizing the benefits of HF therapy in clinical practice. Similarly, type 2 diabetes is frequently comorbid with HF, so both conditions require effective co-management. SGLT-2 inhibitors are now indicated for patients with and without diabetes to treat HF, and PAs need to be aware of these new indications. These areas were identified as foundational areas that require additional education. This program is specifically designed to address these gaps and to promote care that will lead to better patient outcomes among patients with HF. Through the tactical combination of online and print formats, this program will appeal to various learning styles and allow participants to reinforce their knowledge and acquire new skills that can immediately be applied to clinical practice.

Learning Objectives

---

At the conclusion of this activity, the PA should be better able to:
 

• Recognize key diagnostic features of HF and use appropriate diagnostic tests to diagnose chronic HF early in the disease course
• Outline the most up-to-date evidence-based guidelines for the management of chronic HF, including the use of newer pharmacotherapies
• Use appropriate SGLT-2 inhibitor management strategies when addressing chronic heart failure in patients with and without diabetes

Acknowledgment of Commercial Support

---

Supported by independent educational grants from Merck Sharp & Dohme LLC and Novartis Pharmaceuticals Corporation.